10:40 AM EST, 01/28/2025 (MT Newswires) -- 60 Degrees Pharmaceuticals ( SXTP ) said Tuesday it received approval from an investigational review board for a phase 2 clinical study of Arakoda, or tafenoquine, to treat patients with a presumptive diagnosis of chronic babesiosis.

The company expects patient enrollment to start in Q3. Study participants will have experienced "significant" functional impairment for at least six months, the company said.

Babesiosis is a tick-borne illness caused by Babesia parasites that develop and multiply in red blood cells.

60 Degrees shares were down 9.4% in recent trading.

Price: 0.79, Change: -0.08, Percent Change: -9.37